Comparative Effects of Repaglinide Versus Glibenclamide on Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients | ||
| Tikret Journal of Pharmaceutical Sciences | ||
| Article 1, Volume 8, Issue 1, June 2012, Pages 22-28 | ||
| Authors | ||
| Raghad K. Ibrahim; Raad Y. Al-Hamdani | ||
| Abstract | ||
| Repaglinide is an oral prandial glucose regulator indicated for treatment of type 2 diabetic patients through its mechanism in improving first phase insulin secretion which can lower postprandial plasma glucose. To compare the effects of repaglinide versus glibenclamide on glycemic control in newly diagnosed type 2 diabetic patients. Twenty-four recently diagnosed diabetic patients were enrolled in this non-randomized clinical trial. They were classified into two groups, 12 patients received repaglinide and 12 patients received glibenclamide. Fasting plasma glucose (FPG), 2hour postprandial plasma glucose (2h. PPG) and glycated hemoglobin (HbA1c) were measured at the baseline and after 8 weeks follow up. Repaglinide decreased 2h. PPG significantly more than glibenclamide after 8 weeks without significant differences in reducing FPG and HbA1c between both treatment groups after 8 weeks. Repaglinide can be considered as an ideal agent in controlling postprandial hyperglycemia as a monotherapy or in combination with other oral hypoglycemic agents. Repaglinide, glibenclamide, postprandial hyperglycemia. | ||
|
Statistics Article View: 199 PDF Download: 138 |
||